|Day Low/High||217.71 / 217.94|
|52 Wk Low/High||65.54 / 217.94|
Rigrodsky & Long, P.A.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased AveXis, Inc.
Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Jim Cramer says we're seeing powerful reminders that there's a better time to sell than in the teeth of a decline. Investors must use discipline to their advantage.
Here's what you need to know for Monday, April 9.
Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
A look at possible second-quarter M&A activity in the biotech sector.
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
The acquisition is a big move for Novartis CEO Vas Narasimhan, who took the helm in February.
Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
Includes exclusive worldwide rights to AAV9-SMN product and route of administration
Conference call and webcast on February 27 at 4:30 p.m. EST
Investors in AveXis Inc saw new options begin trading this week, for the August 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 221 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.